649 related articles for article (PubMed ID: 36508072)
1. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z; Xing Y; Li B; Li X; Liu B; Wang Y
Mol Biomed; 2022 Dec; 3(1):42. PubMed ID: 36508072
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
König D; Savic Prince S; Rothschild SI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671873
[TBL] [Abstract][Full Text] [Related]
4. New horizons for uncommon mutations in non-small cell lung cancer:
Olmedo ME; Cervera R; Cabezon-Gutierrez L; Lage Y; Corral de la Fuente E; Gómez Rueda A; Mielgo-Rubio X; Trujillo JC; Couñago F
World J Clin Oncol; 2022 Apr; 13(4):276-286. PubMed ID: 35582653
[TBL] [Abstract][Full Text] [Related]
5. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
6. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.
Rothschild SI
Cancers (Basel); 2015 May; 7(2):930-49. PubMed ID: 26018876
[TBL] [Abstract][Full Text] [Related]
8. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
9. Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A; Perol M; Banna GL; Parikh K; Addeo A
Biomark Res; 2024 Feb; 12(1):24. PubMed ID: 38347643
[TBL] [Abstract][Full Text] [Related]
10. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
11. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
12. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Lamberti G; Andrini E; Sisi M; Rizzo A; Parisi C; Di Federico A; Gelsomino F; Ardizzoni A
Crit Rev Oncol Hematol; 2020 Dec; 156():103119. PubMed ID: 33053439
[TBL] [Abstract][Full Text] [Related]
13. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
Li MSC; Mok KKS; Mok TSK
Ann Transl Med; 2023 Aug; 11(10):358. PubMed ID: 37675321
[TBL] [Abstract][Full Text] [Related]
14. Beyond
Farago AF; Azzoli CG
Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than
Seegobin K; Majeed U; Wiest N; Manochakian R; Lou Y; Zhao Y
Front Oncol; 2021; 11():750657. PubMed ID: 34926258
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Bansal P; Osman D; Gan GN; Simon GR; Boumber Y
Front Oncol; 2016; 6():112. PubMed ID: 27200298
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.
Grodzka A; Knopik-Skrocka A; Kowalska K; Kurzawa P; Krzyzaniak M; Stencel K; Bryl M
EXCLI J; 2023; 22():415-432. PubMed ID: 37346803
[TBL] [Abstract][Full Text] [Related]
18. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
19. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
20. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Halliday PR; Blakely CM; Bivona TG
Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
